Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 408

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 408
---
 from 1 April 2023.

| F-67 |

| 21 | Share capital |

| Schedule of detailed information about share capital |     |               |     |           |     |             |     |           |     |             |     |           |
| Authorised, allotted and fully                       
 paid – classified as equity                          |     |   2023 Number |     |    2023 £ |     | 2022 Number |     |    2022 £ |     | 2021 Number |     |    2021 £ |
| At 31 December                                       |     |               |     |           |     |             |     |           |     |             |     |           |
| Ordinary shares of                                   
 £0.001 each                                          |     | 1,189,577,722 |     | 1,189,578 |     |   5,417,137 |     |   108,343 |     |   4,923,420 |     |    98,468 |
| ‘A’ Deferred shares of £1 each                       |     |     1,000,001 |     | 1,000,001 |     |   1,000,001 |     | 1,000,001 |     |   1,000,001 |     | 1,000,001 |
| ‘B’ Deferred shares of £0.001 each                   |     | 4,063,321,418 |     | 4,063,321 |     |           – |     |         – |     |           – |     |         – |
| Total                                                |     |               |     | 6,252,900 |     |             |     | 1,108,344 |     |             |     | 1,098,469 |

At a General Meeting
on 24 March 2023, shareholders approved a consolidation of the Company’s Ordinary Shares on a one for 20 basis. As a result, the
par value of the Ordinary Shares was changed from £0.001 per share to £0.02 per share. At the same time, the ratio of the
Company’s Ordinary Shares to ADSs was changed from each ADS representing 25 Ordinary Shares to each ADS representing five Ordinary
Shares.

At a General Meeting
on 14 June 2023, shareholders approved the subdivision and redesignation of the Company’s Issued Ordinary Shares of £0.02
each into